Abstract Library

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4534 Development of new 3D in vitro models for pancreatic neuroendocrine tumours (PanNETs)

Introduction: Current PanNET in vitro models struggle to accurately replicate the tumour’s biology and microenvironment, limiting understanding of the mechanisms underlying PanNET behaviour and drugs response.

Conference:

Presenting Author:

Authors: Battistella A, Pinos R, Barbaglio F, Capurso G, Schiavo Lena M,

Keywords: Preclinical models, Pan NET, microenvironment, bioprinting, tumour slices, drug testing,

#4397 DNA repair enzyme regulation strategy for enhanced pancreatic neuroendocrine tumour therapy via targeting siRNA-lipid nanoparticles

Introduction: Pancreatic neuroendocrine tumours (panNETs) originate from neuroendocrine cells with high rates of metastasis, rendering many patients’ ineligible for surgical resection. The first-line chemotherapeutic agent temozolomide (TMZ) for metastatic panNETs faces challenges related to resistance, primarily mediated by the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).

Conference:

Presenting Author: Wang F

Authors: Wang F, Xu J, Xu X, Qin Y, Chen J,

Keywords: Lipid nanoparticle, siRNA, DNA repair enzyme, pancreatic neuroendocrine tumour, temozolomide,

#4316 Combination of sorafenib and everolimus regresses pancreatic neuroendocrine tumour significantly in vitro and vivo

Introduction: PNET is a rare group of highly heterogeneous tumours with neuroendocrine differentiation properties. Everolimus is the most promising drug for progressive well-differentiated pNETs. Sorafenib's anti-tumour activity may involve regulation of the mTOR pathway.

Conference:

Presenting Author: Zheng H

Authors: Zheng H,

Keywords: sorafenib, everolimus, pancreatic neuroendocrine tumour, mTOR,

#4293 Efficacy of FOLFOX chemotherapy combined with anti-angiogenic targeted drugs (bevacizumab/surufatinib) in neuroendocrine tumours after progression following multiple lines of therapy: A retrospective study

Introduction: The FOLFOX regimen (combining 5-fluorouracil, leucovorin, and oxaliplatin) has been widely used for treating various cancers, including NETs. However, the effectiveness of combining FOLFOX with antiangiogenic agents in NETs after progression on multiple therapies remains unclear.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Jia X, Sun Z, Chen J,

Keywords: FOLFOX, chemotherapy, antiangiogenic agents, G3,